Optain develops non-invasive clinical support tools that use AI-enabled algorithms to analyse full‑colour retinal images for screening referable eye diseases and assessing broader health risk (including cardiovascular risk screening where enabled). Their technology is designed as evidence‑based, real‑time clinical decision support to improve early detection and patient outcomes.

The company provides Eyetelligence Assure (a Software as a Medical Device) combined with a portable automatic fundus camera as a turnkey solution. The package is ready-to-use, requires minimal training or configuration, integrates easily into clinics, and delivers instant, standardised risk assessment reports to streamline workflows.

Optain’s mission is to democratise access to specialised screening, reduce missed diagnoses, and accelerate speed-to-diagnosis. The team comprises clinicians, scientists, engineers and business leaders led by a world‑leading ophthalmology AI expert. Partners and investors include Northwell Health, Aegis Ventures and Insight Partners.